Atenolol

May be taken with or without food.

Sinus bradycardia, cardiogenic shock, hypotension, metabolic acidosis, 2nd- or 3rd-degree heart block, severe peripheral arterial disease, sick sinus syndrome, uncontrolled cardiac failure, untreated phaeochromocytoma.

Patient with poor cardiac reserve, compensated heart failure, Prinzmetal's angina, peripheral vascular disease, Raynaud's phenomenon, 1st-degree heart block, bronchospastic disease, history of anaphylactic reaction to allergens; diabetes mellitus, myasthenia gravis, psoriasis. Patient undergoing surgery. Avoid abrupt withdrawal. May mask the signs and symptoms of hypoglycaemia and hyperthyroidism (particularly tachycardia). Elderly. Renal impairment. Pregnancy and lactation. Monitoring Parameters Monitor blood pressure and heart rate (before and after initiation of therapy and following any dose changes); serum glucose (in diabetic patients); renal function. Obtain ECG when used for acute cardiac treatment.

Significant: Bradycardia; may exacerbate angina and precipitate MI and ventricular arrhythmias after abrupt discontinuation (in patients with angina); may precipitate or aggravate peripheral arterial insufficiency. Ear and labyrinth disorders: Vertigo. Gastrointestinal disorders: Nausea, diarrhoea, dry mouth. General disorders and administration site conditions: Fatigue, lethargy. Immune system disorders: Hypersensitivity reaction (including urticaria and angioedema). Investigations: Elevated transaminase levels. Musculoskeletal and connective tissue disorders: Lupus-like syndrome. Nervous system disorders: Dizziness, drowsiness. Psychiatric disorders: Sleep disturbances, depression. Skin and subcutaneous tissue disorders: Rarely, exacerbation of psoriasis, psoriasiform skin reactions. Vascular disorders: Cold extremities, hypotension, orthostatic hypotension.

May increase the risk of severe hypotension, bradycardia, and heart failure with diltiazem or verapamil. Additive hypotensive effect with catecholamine-depleting agents (e.g. reserpine) and other Ca channel blockers (e.g. nifedipine). May increase the risk of bradycardia when given with digitalis glycosides. May enhance the rebound hypertension that can follow the withdrawal of clonidine. Potentiates the effect on atrial conduction time and induces a negative inotropic effect with class I antiarrhythmic agents (e.g. disopyramide) and amiodarone. May diminish the therapeutic effect of sympathomimetic agents (e.g. epinephrine). May potentiate the hypoglycaemic effects of insulin and oral antidiabetic agents. Concomitant use with NSAIDs (e.g. ibuprofen, indometacin) may decrease the hypotensive effect of atenolol. May increase the risk of hypotension and attenuate reflex tachycardia with anaesthetic drugs (e.g. methoxyflurane).

Anti-Anginal Drugs / Beta-Blockers

C07AB03 - atenolol ; Belongs to the class of selective beta-blocking agents. Used in the treatment of cardiovascular diseases.